Cochlear Limited acquires Oticon Medical (2022)

Deal facts

Buyer: Cochlear Limited
Target: Oticon Medical
Deal value: Not disclosed
Announced: 11 October 2022
Status: In review
Sector: Healthcare
Country: Denmark
Consideration: cash

Sources

UK_CMA_GOVUK

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

11 Oct 2022CMA Phase 1 launched
Cochlear / Oticon merger inquiry
The CMA investigated the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical. Phase 2 Administrative timetable Referral date: 20 December 2022 Statutory deadline: 31 July 2023 Administrative timetable (PDF, 103KB) (18.5.23) Contact general.enquiries@cma.gov.uk Case closure summary 29 May 2024: On 17 May 2
UK CMA

OpinionExit Mode editorial

We see a clear strategic signal in Cochlear Limited's move to acquire Oticon Medical. This is a cross-border consolidation within the hearing implant sector, bringing together an Australian leader with a Danish specialist. The deal is structured as a cash consideration, which removes the immediate dilution risk for the target's shareholders and simplifies the capital structure for the combined entity. For the SME founder watching this space, the choice of cash over stock often indicates a buyer confident in their own balance sheet and eager to secure full control without sharing future upside.

The transaction is currently in review, a status that demands attention to regulatory mechanics. With the buyer based in Australia and the target in Denmark, this deal triggers scrutiny under both EU competition law and Australian merger guidelines. The European Commission will likely examine whether combining these two entities creates a dominant position in the niche market for implantable hearing solutions. We must also consider change-of-control covenants that may exist in the target's existing debt or licensing agreements, which could be triggered by this sale. The absence of a disclosed value suggests the parties are prioritizing regulatory clearance over immediate market spectacle, a prudent approach in a sector where antitrust thresholds are strictly enforced.

This acquisition highlights a broader trend where established players are buying capability rather than building it organically. In healthcare, where R&D cycles are long and regulatory hurdles are high, buying a proven product line with an established European footprint is often faster than internal development. However, the in-review status means the deal is not done. The timeline will depend on how the competition authorities assess the impact on patient choice and pricing. Founders in this sector should note that cash deals do not guarantee a smooth path to completion if the regulatory bodies perceive a threat to competition.

Your immediate action this week is to map your own customer concentration against the relevant competition thresholds in your primary markets. If your top three clients represent more than a specific share of your revenue, or if your acquisition would create a dominant position in a niche, you must prepare a robust regulatory defence strategy before you even sign a term sheet. Do not assume a cash offer guarantees a quick close; the regulatory review process can kill a deal regardless of the price tag.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More strategic acquisition deals More from Cochlear Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history